Regulatory Innovation in New Drug Development: The DDT Qualification Program

The U.S. Food and Drug Administration (FDA) operates the Drug Development Tool (DDT) qualification program to maximize the efficiency of new drug development. This program officially validates the reliability of biomarkers or clinical outcome assessments (COAs) that are repeatedly used in the new drug development process, based on 21st-century cures. Qualified tools do not need to be re-validated at the individual clinical trial approval stage, which significantly reduces the time and regulatory hurdles in new drug R&D. This provides substantial regulatory benefits to the pharmaceutical industry, leading to reduced clinical costs and faster drug launches.

Addressing the Challenges of Liver Toxicity Assessment and GLDH Qualification

A recent success story in this program is the qualification of glutamate dehydrogenase (GLDH) as a biomarker, led by the Critical Path Institute's (C-Path) Predictive Safety Testing Consortium (PSTC). Existing liver injury assessment indicators, ALT and AST, are also present in muscle cells, causing significant errors in identifying liver toxicity in patients with Duchenne muscular dystrophy (DMD). DMD patients have persistently elevated ALT and AST levels due to muscle breakdown, making it difficult to distinguish drug-induced liver injury (DILI). GLDH, a mitochondrial enzyme specific to liver cells, eliminates these false-positive signals, enabling accurate safety assessments.

Reducing Clinical Failure Rates and Impacting the Global Market

Drug-induced liver injury (DILI) is a major cause of new drug clinical trial discontinuation and market withdrawal. Introducing a validated biomarker like GLDH into the design can prevent unnecessary clinical trial terminations or regulatory delays, saving billions of dollars in R&D. It also significantly improves the clinical success rate of innovative new drug developers, such as Sarepta Therapeutics, which develops treatments for muscular dystrophies. As a result, patients will have access to safer and more effective treatments more quickly, and healthcare costs will be significantly reduced.

Competition with Overseas Regulatory Agencies and Regulatory Harmonization

The European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan also operate regulatory science programs to support new technologies and methodologies. However, the FDA's DDT qualification program exerts a strong influence as a de facto global standard in the global pharmaceutical market. In the future, the FDA will further lead regulatory harmonization by fully implementing the ISTAND program, which supports artificial intelligence (AI)-based models and organ-on-a-chip technologies. Global bio companies can reduce barriers to entry into the U.S. market and accelerate multi-national approvals by complying with FDA standards.

Venture Capital Investment Strategy and Future Prospects

From the perspective of venture capital (VC) and investors, the FDA's DDT qualification is a key milestone for evaluating pipeline value. New drug developers with validated development tools have lower regulatory approval failure rates and higher confidence in target validation, making them more attractive to investors. Technology companies that develop AI-based analysis tools and digital health technologies can also maximize their corporate value in a short period of time by entering the ISTAND program. Validated biomarker technologies are also a powerful asset in license-out (L/O) negotiations for early-stage biotech companies, giving them a significant advantage.